About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

An 8 Week Study Of Adults Diagnosed With Major Depressive Disorder

NCT00057226·21 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

GlaxoSmithKline

Age

18–64

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Diagnosis of Major Depressive Disorder (MDD)
Duration of current depressive episode 12 weeks - 24 months
Patients can read and write at a level sufficient to provide a signed consent
If female, patients must be practicing an acceptable method of birth control

You may not be if

Patients have other psychiatric disorders that would affect patient's response to treatment
Patients have not responded to two or more adequate courses of antidepressant therapy
Patients cannot be currently abusing illicit drugs or alcohol
Patients are not currently receiving psychotherapy
Patients have received electroconvulsive therapy within 6 months prior to screening
Patients are pregnant or lactating

The record

StatusCompleted

PhasePhase 2

Taking part365

StartedMar 2003

UpdatedApr 16, 2015

Conditions

Depressive Disorder, Major

Where21

GSK Investigational Site
Cerritos, California, United States
GSK Investigational Site
San Diego, California, United States
GSK Investigational Site
Washington D.C., District of Columbia, United States

Clareo Health | An 8 Week Study Of Adults Diagnosed With Major Depressive Disorder